Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has seen a significant increase in estimated market value to $4.44 billion, reflecting a favorable outlook due to its accelerated approval timelines for key product Axpaxli. The company's strategic shift in regulatory approach suggests that the NDA filing for Axpaxli could now occur as early as 2027, representing an acceleration of approximately 12-15 months, which strengthens its competitive position in the ophthalmics market. Additionally, strong enrollment in the SOL-R trial underscores demand for Ocular Therapeutix's innovative therapies, enhancing the company's prospects as it positions itself for potential commercialization.

Bears say

Ocular Therapeutix Inc has faced substantial financial losses since its inception, raising concerns about its long-term viability. The company is under significant pressure from competition, as both existing and emerging therapies target similar ophthalmic indications, which may adversely affect its market penetration and pricing strategy. Additionally, potential delays in clinical development, regulatory approvals, or commercialization could prolong development timelines and escalate costs, further complicating the company's financial outlook.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.